Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m² in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.

ABSTRACT:

Aim

To explore the effects of sex and baseline body mass index (BMI) on the efficacy and safety of survodutide in people with a BMI ≥27 kg/m².

Materials and methods

Totally 387 people (aged 18-75 years, BMI ≥27 kg/m², without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance). Participants were categorized according to sex and baseline BMI. Data were analysed descriptively for the full analysis set (FAS), according to dose assigned at randomization (planned treatment) using on-treatment data or all data censored for COVID-19-related treatment discontinuations. (ClinicalTrials.gov number: NCT04667377).

Results

After 46 wee

SUBMITTER: le Roux CW 

PROVIDER: S-EPMC11885088 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature